SCHEDULE: Balyasny Asset Management Discloses 2.42% Stake in Avalo Therapeutics

Balyasny Asset Management and its affiliates reported a passive beneficial ownership of 2.42% in Avalo Therapeutics Inc., totaling 439,312 shares.

Summary

• Balyasny Asset Management L.P. and its affiliated entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) collectively reported beneficial ownership of 439,312 shares of Avalo Therapeutics Inc. common stock.
• This represents approximately 2.42% of Avalo Therapeutics Inc.'s outstanding Class A common stock, based on 18,133,698 shares outstanding as of November 3, 2025.
• The shares are held directly by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P.
• The reporting persons have sole voting power and sole dispositive power over all 439,312 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of a passive, non-controlling ownership stake by an institutional investor, providing transparency without indicating significant positive or negative operational developments for Avalo Therapeutics.

Positives

• An established institutional investor, Balyasny Asset Management, holds a stake in Avalo Therapeutics, potentially indicating a level of confidence in the company's long-term prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal institutional interest in a company within the biotechnology or pharmaceutical sector. While a 2.42% passive stake is not a controlling interest, it indicates Balyasny Asset Management's position as a minor shareholder in Avalo Therapeutics, a company focused on developing therapies.

Comparison to Industry Standards

• A 2.42% passive stake is typical for institutional investors taking positions in smaller-cap biotechnology companies like Avalo Therapeutics, often as part of a diversified portfolio.
• Compared to activist stakes (typically 5% or more, filed on Schedule 13D), this passive 13G filing indicates no immediate intent to influence management or corporate strategy, aligning with standard investment fund practices for non-controlling positions.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, confirming Balyasny Asset Management as a minor shareholder. This passive stake does not suggest any immediate impact on corporate control or strategy.
• Management: No direct impact on management or operations, as the stake is passive and below the 5% threshold for more active engagement.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive, non-controlling ownership stake by an institutional investor. It does not provide new information regarding Avalo Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this information as part of broader due diligence, focusing on the company's core business fundamentals rather than this ownership update alone.

Keywords

Avalo Therapeutics, Balyasny Asset Management, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake